Related Experiment Video

Updated: Jun 13, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

On target? The challenge of integrating biomarker research in drug development. Interview with Walter Carney

Walter Carney

    Biomarkers in Medicine
    |May 19, 2010
    PubMed

    Insights

    Industry faces challenges integrating biomarker research into medicine. Dr. Walter Carney, a pioneer in linking diagnostics with medicines, discusses integrating circulating biomarkers and imaging biomarkers for targeted therapies.

    Area of Science:

    • Oncology
    • Biomarker Research
    • Translational Medicine

    Background:

    • Industry struggles to implement advances in biomarker research into drug development and healthcare.
    • Dr. Walter Carney's pioneering work in linking diagnostics with medicines for targeted therapies is highlighted.
    • The discovery of the circulating human epidermal growth factor receptor (HER)2/neu oncoprotein in metastatic breast cancer by Dr. Carney's team is a key achievement.

    Discussion:

    • Exploration of challenges in translating biomarker discoveries into clinical practice.
    • Dr. Carney's extensive experience in diagnostics, drug development, and biomarker commercialization is detailed.
    • The evolution of Oncogene Science from its inception to its integration into global diagnostics companies is traced.

    Key Insights:

    • Biomarker research holds immense potential for personalized medicine and targeted therapies.
    • Integrating circulating and imaging biomarkers is crucial for advancing oncology diagnostics and therapeutics.
    • The commercialization pathway for biomarker-based diagnostics requires strategic industry collaboration.

    Outlook:

    • Future innovations in diagnostics and pharmaceuticals will be driven by integrated biomarker approaches.
    • The development of novel biomarker tests will continue to link diagnostics with pharmaceutical development.
    • The trend towards integrated diagnostics companies signifies a move towards comprehensive healthcare solutions.

    More Related Videos

    Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances07:35

    Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

    Published on: October 11, 2018

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Drug Discovery: Overview01:26

    Drug Discovery: Overview

    Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Targets for Drug Action: Overview01:26

    Targets for Drug Action: Overview

    Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
    Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...